Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
| Autor: | Noriyoshi Ogawa, Hiroyuki Ohashi, Yasuhiro Ota, Kaori Kobori, Motohiro Suzuki, Seiji Tsuboi, Masakatsu Hayakawa, Yoshinori Goto, Taro Karahashi, Osamu Kimoto, Toshiaki Miyamoto, Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki, Yuichiro Maekawa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Immunological Medicine, Vol 42, Iss 1, Pp 29-38 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2578-5826 25785826 |
| DOI: | 10.1080/25785826.2019.1605036 |
| Popis: | The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0 ± 2.7 mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1- and 2-year retention rates were 77% and 53%, respectively. At 24-months, the DAS28-CRP remission rates were 62.8% in the biologic-naïve patients, and 33.3% in the biologic-failure patients (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|